No.
|
T-F-004
|
---|---|
Date
|
01-10-2024
|
To
|
Respective Contractors
|
Invitation for Fit-Out work for New Opining branches and Lease hold improvement for existing branches across the whole Kingdom.
Dears,
We are pleased to invite your esteemed company to participate in our new fit-out and construction tender. The tender will be for constructing new branches and lease hold improvement for existing braches.
The scope of work for new pharmacies should include; submitting approved shop drawings, by supplying, fabricating, and performing all the Civil, Architectural and Finishing, MEP, and Fit-Out works, according to the approved specifications, and material submittals.
The scope of work for the Lease Hold improvements will include finishing works, and Electro-Mechanical works….etc.).
The locations of the involved branches, will be across the Kingdom.
For further clarifications in order to get the full details, terms, conditions and along with the tender documents, you can communicate with us on the below E-mail Address.
Note that: your offer should be in two separate envelopes closed and sealed (one for technical and supporting documents and another envelope containing only the commercial proposal). You have to include in your proposal your price/ sqm based on the typical Pharmacy theme, specification and standard as part of commercial offer proposal Document. The price should be clear and in the local currency.
In your technical proposal you have to include organizational chart, proposed
project key personnel and CVs, government legal document and certificates which include (commercial register of the company, certificate of registration with added tax, certificate from the Social Insurance Corporation, certificate of the Chamber of Commerce, certificate of Saudi Contractors Authority), QAQC procedures and certificates, HSE plans, project execution plan, plant & equipment, manpower histogram, past and similar experiences, company profile document.
Note that: the submitted offers will be technically evaluated according to the following:
– Availability of all the documents mentioned above in the technical proposal.
– The size of similar projects implemented by companies.
– Quality assurance standards
– Experience years in the field.
All queries about the bidding procedure shall be provided before 31 October 2024.
The Final Technical and Commercial Proposals shall be submitted on 14 November. 2024, before 5:00 pm.
The result of the bidding will be announced on 28 November 2024.
No consideration will be given to any proposal submitted after the above specified date and time.
Best regards and good luck for all
Support Services management
The following pages contain information relating to an initial public offering and a listing of securities of Al-Dawaa Medical Services Company (the “Company”). This information may not be accessed by residents of certain countries based on applicable securities law regulations.
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW.
The following pages include information pertaining to an initial public offering and a listing of securities of the Company.
This website and the information contained herein are not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in United States of America (including its territories and possessions), any state of the United States and the District of Columbia (the “United States”), Australia, Canada, Japan or South Africa, and do not constitute an offer to sell or the solicitation of an offer to purchase or acquire, any securities of the Company in the United States, Australia, Canada, Japan, South Africa or in any other jurisdiction in which such offer or solicitation would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
The securities of the Company referred to on this website have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act.
All persons residing outside of the United States, Australia, Canada, Japan and South Africa who wish to access the documents contained on this website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this website, or require registration or approval for any acquisition of securities by them. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.
If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
Access to electronic versions of these materials is being made available on this webpage by the Company in good faith and for information purposes only.
By clicking “Yes” you confirm and certify that: (i) you are not a resident of or physically present in the United States, Australia, Canada, Japan, South Africa or any other restricted jurisdiction; and (ii) you are authorised to access this information pursuant to applicable laws or regulations of your jurisdiction.